Targeting Cd276 Autologous Chimeric Antigen Receptor T Cells
Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyN/ADormant
D
26/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 59/ 100
Competitive context
928 Active assets in the Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Inno-206 The First Affiliated Hospital of Soochow University | Phase 2/3 | BB |
DINITROGEN MONOXIDE Medical College of Wisconsin | Phase 4 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Targeting Cd276 Autologous Chimeric Antigen Receptor T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →